Lilly Provides Update on CEO Dr. John Lechleiter

INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery for a dilated aorta on Monday, May 13, 2013.

"Dr. Lechleiter's surgeons have advised us that surgery went as expected and the repair to the aorta is functioning as intended," said Kristine A. Courtney, M.D., senior director of Lilly's corporate health services.  "Dr. Lechleiter is recovering and will be closely monitored by the medical staff over the next several days."

As announced previously, in accordance with the company's bylaws, Derica W. Rice, executive vice president, global services and chief financial officer, has assumed the additional role of acting chief executive officer during Lechleiter's recuperation period.  Ellen R. Marram, currently the board's lead independent director, is serving as acting chairperson of the board of directors.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at C-LLY

(Logo: )

Refer to:  

(317) 433-9899 – Edward Sagebiel; [email protected]

(317) 276-5795 – Mark Taylor; [email protected]

SOURCE Eli Lilly and Company

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.